Eli Lilly and Company (NYSE:LLY) Shares Sold by First National Corp MA ADV

First National Corp MA ADV cut its stake in Eli Lilly and Company (NYSE:LLY) by 4.8% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 6,973 shares of the company’s stock after selling 355 shares during the quarter. Eli Lilly and Company makes up approximately 1.0% of First National Corp MA ADV’s investment portfolio, making the stock its 28th largest position. First National Corp MA ADV’s holdings in Eli Lilly and Company were worth $4,065,000 at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. Simon Quick Advisors LLC raised its stake in shares of Eli Lilly and Company by 10.5% during the 4th quarter. Simon Quick Advisors LLC now owns 2,927 shares of the company’s stock worth $1,706,000 after buying an additional 278 shares during the period. Liontrust Investment Partners LLP acquired a new position in Eli Lilly and Company in the 3rd quarter valued at $8,326,000. Armstrong Fleming & Moore Inc acquired a new position in Eli Lilly and Company in the 2nd quarter valued at $357,000. Redhawk Wealth Advisors Inc. raised its stake in Eli Lilly and Company by 0.9% in the 3rd quarter. Redhawk Wealth Advisors Inc. now owns 6,986 shares of the company’s stock valued at $3,752,000 after purchasing an additional 65 shares during the last quarter. Finally, Assenagon Asset Management S.A. raised its stake in Eli Lilly and Company by 4.0% in the 3rd quarter. Assenagon Asset Management S.A. now owns 474,940 shares of the company’s stock valued at $255,105,000 after purchasing an additional 18,079 shares during the last quarter. 82.53% of the stock is owned by institutional investors and hedge funds.

Eli Lilly and Company Trading Down 0.0 %

Shares of LLY stock opened at $778.13 on Thursday. The business’s fifty day moving average price is $727.96 and its 200 day moving average price is $636.01. Eli Lilly and Company has a 1-year low of $334.58 and a 1-year high of $800.78. The firm has a market capitalization of $739.35 billion, a PE ratio of 134.26, a P/E/G ratio of 1.70 and a beta of 0.34. The company has a debt-to-equity ratio of 1.69, a current ratio of 0.94 and a quick ratio of 0.73.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Tuesday, February 6th. The company reported $2.49 earnings per share for the quarter, topping analysts’ consensus estimates of $2.30 by $0.19. The firm had revenue of $9.35 billion for the quarter, compared to analyst estimates of $8.95 billion. Eli Lilly and Company had a return on equity of 51.22% and a net margin of 15.36%. Eli Lilly and Company’s quarterly revenue was up 28.1% on a year-over-year basis. During the same quarter in the prior year, the company posted $2.09 earnings per share. As a group, sell-side analysts forecast that Eli Lilly and Company will post 12.42 EPS for the current fiscal year.

Insiders Place Their Bets

In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 78,573 shares of the business’s stock in a transaction on Wednesday, January 31st. The stock was sold at an average price of $648.07, for a total transaction of $50,920,804.11. Following the sale, the insider now directly owns 99,333,810 shares in the company, valued at $64,375,262,246.70. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Over the last ninety days, insiders have sold 195,055 shares of company stock worth $125,254,657. 0.13% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

Several research analysts recently commented on the company. Morgan Stanley increased their price objective on Eli Lilly and Company from $805.00 to $950.00 and gave the company an “overweight” rating in a research note on Friday, February 16th. Truist Financial restated a “buy” rating and issued a $850.00 target price on shares of Eli Lilly and Company in a report on Friday, March 22nd. BMO Capital Markets upped their target price on Eli Lilly and Company from $710.00 to $865.00 and gave the company an “outperform” rating in a report on Wednesday, February 7th. Barclays increased their price target on Eli Lilly and Company from $680.00 to $810.00 and gave the stock an “overweight” rating in a report on Wednesday, February 7th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $815.00 price target on shares of Eli Lilly and Company in a report on Tuesday, February 20th. Three analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $689.52.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.